In particular, cancer immunotherapy approaches based on the blockade of inhibitory immune checkpoints, such as PD-1, CTLA-4, and PDL-1, have shown promise in clinical settings and are being recognized for their capacity to reinstate antigen-specific CD8 T cell attack on cancers. This evidence concerns the gene CTLA4 and cancer.